Research ArticleTherapeutic Antibodies
Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
- Jessica A. Couch1,*,
- Y. Joy Yu2,*,
- Yin Zhang3,
- Jacqueline M. Tarrant1,
- Reina N. Fuji1,
- William J. Meilandt2,
- Hilda Solanoy2,
- Raymond K. Tong4,
- Kwame Hoyte5,
- Wilman Luk5,
- Yanmei Lu5,
- Kapil Gadkar1,
- Saileta Prabhu1,
- Benjamin A. Ordonia1,
- Quyen Nguyen1,
- Yuwen Lin1,
- Zhonghua Lin6,
- Mercedesz Balazs6,
- Kimberly Scearce-Levie2,
- James A. Ernst4,
- Mark S. Dennis3,† and
- Ryan J. Watts2,†
- 1Development Sciences, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
- 2Neurodegeneration Labs, Department of Neuroscience, Genentech Inc., South San Francisco, CA 94080, USA.
- 3Antibody Engineering, Genentech Inc., South San Francisco, CA 94080, USA.
- 4Protein Chemistry, Genentech Inc., South San Francisco, CA 94080, USA.
- 5Biochemical and Cellular Pharmacology, Genentech Inc., South San Francisco, CA 94080, USA.
- 6Translational Immunology, Genentech Inc., South San Francisco, CA 94080, USA.
- ↵†Corresponding author. E-mail: rwatts{at}gene.com (R.J.W.); msd{at}gene.com (M.S.D.)
See allHide authors and affiliations
Science Translational Medicine 01 May 2013:
Vol. 5, Issue 183, pp. 183ra57
DOI: 10.1126/scitranslmed.3005338
